Combination Antibody Therapy for Cancer Treatment
The report consists of 8 chapters which address different aspect of the issue of combined antibody therapy, past, present and future. The first chapter provides an introduction and a review of currently approved antibody-based drugs. We weight their clini
(EMAILWIRE.COM, May 03, 2018 )
MarketIntelReports, Singapore, April 30, 2018.
MarketIntelReports : A global report titled Combination Antibody Therapy Market has been introduced into our library of 2.5 million reports.
Title of the report: Combination Antibody Therapy for Cancer Treatment
Year: 2018
Details in the report: This is a 180+ page report with 8 chapters which includes demand analysis by country, application, manufacturers, product categories. Report also includes key developments, market share analysis, market sizing by country, market trends/ future trends, strategic initiatives, key product launches as well.
About the market report:
The report consists of eight chapters which address different aspect of the issue of combined antibody therapy, past, present and future. The first chapter provides an introduction and a review of currently approved antibody-based drugs. We weight their clinical efficacy against various side effects and consider their promise for combination therapeutic regimes.
Chapter 2 considers targeted antibody therapeutics.The third chapter deals with the development of combination chemotherapy and immuno-antibody therapeutics.
To access the full table of contents of the report click below: https://www.marketintelreports.com/report/ipr0002/combination-antibody-therapy-for-cancer-treatment
The fourth chapter reviews the general topic of antibody drug conjugates and antibody biologics conjugates, including therapeutic modalities based on fusion molecules and other anticancer drug combinations.
Multifunctional and polytargeted antibodies are an important area of investigative combination therapy, as revealed in Chapter 5.
There are 8 Chapters to deeply display the Combination Antibody Therapy Market
To find out more of the report or request some customization: https://www.marketintelreports.com/inquiry-before-buying.php?id=ipr0002
Table of Contents-Key Points Covered
Executive Summary
Background
Topics covered in this report
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Chapter 8
Outlook for combination antibody therapeutics
CHAPTER 1
Introduction, Scope and Objectives
A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
Bevacizumab
Necitumumab
Dinutuximab.
Nivolumab.
Blinatumomab
Pembrolizumab
Ramucirumab
Obinutuzumab
Ado-trastuzumab emtansine
Ipilimumab: Immune checkpoint inhibitors
Pertuzumab.
Opportunities and challenges for future development
1.2.1. A need for targets.
Safety concerns.
Objectives and outlook for combination antibody therapy
1.3.1. Overcoming resistance to anti-cancer agents.
1.3.2. Uncertainties in combined antibody therapy.
1.4. Summary
CHAPTER 2
Targeted Antibody Therapeutics
2.1. The unstable cancer genome.
2.2. The epigenome.
2.3. Chemotherapy treatment combined with antibodies
2.4. Combinations of targeted antibodies
2.5. Targeted antibody therapeutics and the marketplace
2.6. Targeted antibody therapeutics in the clinic
2.7. Summary
CHAPTER 3
Immuno-Antibody Therapeutics
Development and Current Products
Combination of Chemotherapy and Immuno-antibody therapeutics
Combinations of immune-antibodies
Immuno- antibody therapeutics in the marketplace
3.5. Immuno- antibody therapeutics in the clinic
Summary
CHAPTER 4:
Continued…..
Complete Report Details @ https://www.marketintelreports.com/report/ipr0002/combination-antibody-therapy-for-cancer-treatment
Contact us for any queries on the report:
Lakshmi
Sales Manager
Email : sales@marketintelreports.com
www.marketintelreports.com
Contact Sales: 1-302-261-5343
About us:
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
MarketIntelReports, Singapore, April 30, 2018.
MarketIntelReports : A global report titled Combination Antibody Therapy Market has been introduced into our library of 2.5 million reports.
Title of the report: Combination Antibody Therapy for Cancer Treatment
Year: 2018
Details in the report: This is a 180+ page report with 8 chapters which includes demand analysis by country, application, manufacturers, product categories. Report also includes key developments, market share analysis, market sizing by country, market trends/ future trends, strategic initiatives, key product launches as well.
About the market report:
The report consists of eight chapters which address different aspect of the issue of combined antibody therapy, past, present and future. The first chapter provides an introduction and a review of currently approved antibody-based drugs. We weight their clinical efficacy against various side effects and consider their promise for combination therapeutic regimes.
Chapter 2 considers targeted antibody therapeutics.The third chapter deals with the development of combination chemotherapy and immuno-antibody therapeutics.
To access the full table of contents of the report click below: https://www.marketintelreports.com/report/ipr0002/combination-antibody-therapy-for-cancer-treatment
The fourth chapter reviews the general topic of antibody drug conjugates and antibody biologics conjugates, including therapeutic modalities based on fusion molecules and other anticancer drug combinations.
Multifunctional and polytargeted antibodies are an important area of investigative combination therapy, as revealed in Chapter 5.
There are 8 Chapters to deeply display the Combination Antibody Therapy Market
To find out more of the report or request some customization: https://www.marketintelreports.com/inquiry-before-buying.php?id=ipr0002
Table of Contents-Key Points Covered
Executive Summary
Background
Topics covered in this report
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Chapter 8
Outlook for combination antibody therapeutics
CHAPTER 1
Introduction, Scope and Objectives
A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
Bevacizumab
Necitumumab
Dinutuximab.
Nivolumab.
Blinatumomab
Pembrolizumab
Ramucirumab
Obinutuzumab
Ado-trastuzumab emtansine
Ipilimumab: Immune checkpoint inhibitors
Pertuzumab.
Opportunities and challenges for future development
1.2.1. A need for targets.
Safety concerns.
Objectives and outlook for combination antibody therapy
1.3.1. Overcoming resistance to anti-cancer agents.
1.3.2. Uncertainties in combined antibody therapy.
1.4. Summary
CHAPTER 2
Targeted Antibody Therapeutics
2.1. The unstable cancer genome.
2.2. The epigenome.
2.3. Chemotherapy treatment combined with antibodies
2.4. Combinations of targeted antibodies
2.5. Targeted antibody therapeutics and the marketplace
2.6. Targeted antibody therapeutics in the clinic
2.7. Summary
CHAPTER 3
Immuno-Antibody Therapeutics
Development and Current Products
Combination of Chemotherapy and Immuno-antibody therapeutics
Combinations of immune-antibodies
Immuno- antibody therapeutics in the marketplace
3.5. Immuno- antibody therapeutics in the clinic
Summary
CHAPTER 4:
Continued…..
Complete Report Details @ https://www.marketintelreports.com/report/ipr0002/combination-antibody-therapy-for-cancer-treatment
Contact us for any queries on the report:
Lakshmi
Sales Manager
Email : sales@marketintelreports.com
www.marketintelreports.com
Contact Sales: 1-302-261-5343
About us:
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Contact Information:
MarketIntelReports
Venkat
Tel: 1-302-261-5343
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
MarketIntelReports
Venkat
Tel: 1-302-261-5343
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results